(Q36929714)

English

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

scientific article published on 14 October 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

phase II clinical trial

0 references

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

object named as

Jane N Winter

9

0 references

object named as

Chitra M Hosing

13

0 references

object named as

Leo I Gordon

24

0 references

Hillard M. Lazarus

16

object named as

Hillard M Lazarus

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

12

object named as

David A Rizzieri

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Edmund K Waller

22

object named as

Edmund K Waller

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Steven M Devine

4

object named as

Steven M Devine

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Philippe Armand

1

object named as

Philippe Armand

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Arnon Nagler

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Edie A Weller

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

David E Avigan

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yi-Bin Chen

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Mark S Kaminski

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

H Kent Holland

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

James R Mason

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Joseph W Fay

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Edward D Ball

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Joseph P Uberti

15

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Markus Y Mapara

17

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Stephanie A Gregory

18

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

John M Timmerman

19

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

David Andorsky

20

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Reuven Or

21

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Rinat Rotem-Yehudar

23

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

14 October 2013

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

31

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

33

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

4199-4206

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

The PD-1 pathway in tolerance and autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

PD-1 and its ligands in tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Immune reconstitution after autologous hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 December 2018

Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.48.3685

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36929714&oldid=2133323186"